Insulin icodec/semaglutide explained

Type:	combo
Component1:	Insulin icodec
Class1:	Insulin analog
Component2:	Semaglutide
Class2:	GLP-1 receptor agonist
Tradename:	IcoSema
Legal Status:	Investigational

Insulin icodec/semaglutide, or IcoSema, is a combination medication of insulin icodec and semaglutide in development for type 2 diabetes by Novo Nordisk. It is injected once weekly.^{[1] [2] [3]}

Notes and References

1. Kalra . Sanjay . Bhattacharya . Saptarshi . Kapoor . Nitin . Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs) . Diabetes Therapy . August 2021 . 12 . 8 . 2133–2147 . 10.1007/s13300-021-01113-y . 34268675 . 8342688 . 1869-6953.
2. Web site: CTG Labs - NCBI . clinicaltrials.gov . 5 November 2023.
3. Web site: Novo Nordisk's Insulin Products, Pipeline May Energize The Stock (NYSE:NVO) Seeking Alpha . seekingalpha.com . 5 November 2023 . en . 12 February 2020.